GEMCITABINE AND CAPECITABINE IN UNRESECTABLE OR METASTATIC CHOLANGIOCARCINOMA

吉西他滨和卡培他滨治疗不可切除或转移性胆管癌

• 批准号: 7376317
• 负责人: ALAN D MILLER
• 金额: $ 0.25万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376317
• 关键词: GEMCITABINE; CAPECITABINE; UNRESECTABLE; METASTATIC; CHOLANGIOCARCINOMA

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to find out what effect (good and bad) the combination of the drugs capecitabine and gemcitabine will have on your tumor. This research is being done because right now there is no curative treatment for this type of cancer. Standard chemotherapy causes the tumor to shrink in 10%-15% of people with unresectable gallbladder or cholangiocarcinoma, but those responses last only 3-6 months. Better therapies are needed to treat patients with this disease. The patient will be asked for permission to submit their tissue samples and blood samples to that they may be studied. Scientist will study their tissue to see if they can predict survival by testing certain aspects of their tumor tissue. If they agree, tumor tissue that is left from the biopsy they have before they register to this study will be used for these tests. The blood sample will be taken before they start treatment. A consent form for use of specimens for research has information about using their tissue for research and asks if they will agree to allow us to keep some of the tissue that is left and use it for future studies.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。这项研究的目的是找出药物代甲滨和吉西他滨药物的结合对您的肿瘤有什么作用（好与坏）。 这项研究之所以进行，是因为目前尚无治疗治疗这种类型的癌症。标准化学疗法导致肿瘤在10％-15％的胆囊或胆管癌的患者中收缩，但这些反应仅持续3-6个月。需要更好的疗法来治疗这种疾病的患者。 将要求患者允许将其组织样本和血液样本提交可能会研究。科学家将研究他们的组织，以查看他们是否可以通过测试其肿瘤组织的某些方面来预测生存。如果他们同意，则在注册之前进行的活检中留下的肿瘤组织将用于这些测试。血液样本将在开始治疗之前先采用。 用于研究标本的同意书有有关使用其组织进行研究的信息，并询问他们是否同意让我们保留剩下的一些组织并将其用于将来的研究。